Cystourethroscopes

Welcome to Cystourethroscopes Site
Cystourethroscopes Resources

Home > Cystourethroscopes > Promising Results For VX-770, An Oral Investigational Agent That Targets A Defective Protein Responsible For Cystic Fibrosis

Promising Results For VX-770, An Oral Investigational Agent That Targets A Defective Protein Responsible For Cystic Fibrosis



At the 31st European Cystic Fibrosis Society (ECFS) Annual Meeting in Prague, Czech Republic, researchers presented interim results from the first clinical trial of the investigational oral agent VX-770 in cystic fibrosis patients.


Click Here to read the entire article...



Other Articles:


• Listen to The Lancet: 14 June
In this week's podcast, David Shlim from Jackson Hole Travel Centre, Wyoming, USA, assesses the phase II study of Frech and colleagues suggesting that a skin patch could have therapeutic value in protecting against the most common cause of travellers' diarrhoea, that caused by the pathogen enterotoxigenic Escherichia coli.
Click Here to read the entire article...
• Cell Biologists Hail Senate Passage of Stem Cell Bill
Expanding the number of human embryonic stem cells available for use by U.S. government-funded researchers was approved by the Senate with its passage of H.R. 810, 63 - 37. American Society for Cell Biology President Mary Beckerle praised the United
Click Here to read the entire article...
• Zoom RhythmTrak RT-223 - USED
£38.00 (0 Bid)
End Date: Monday Aug-04-2008 22:43:54 BST
Bid now | Add to watch list
Click Here to read the entire article...
• Medtech Startups, November 2007
New medical technologies represented in companies added (November 2007) to the Medtech Startups Database and/or added to the November 2007 issue of MedMarkets.

The following are brief technology descriptions for companies newly added to the MedMarket Diligence Medtech Startups Database and/or covered in MedMarkets Startups during the month of November:

  • Development of a miniature retrievable pump for use in improving blood flow following coronary artery angioplasty.
  • Technology for anchoring dynamic and static spinal implants.
  • Intervertebral disc and facet joint prosthesis in spine surgery.
  • Static compression device technology in spine surgery.
  • Intramedullary transillumination apparatus for use in bone repair.
  • Company has licensed technology from major technology university that creates colony of liver cells that can be used for testing drug toxicity.
  • Diagnostic and therapeutic tools for the treatment of patients who are prone to develop unstable coronary syndromes due to the presence of multiple thrombogenic vulnerable plaques.
  • Device for treatment of chronic renal insufficiency.
  • Developing the brachytherapy applicator for radiation following lumpectomy.
  • Development of catheters and other technologies for the treatment of acute and chronic total occlusion in coronary and peripheral arteries.
  • Stents and stent sleeves that minimize embolism.



Now Published!: Worldwide Wound Management 2007-2016. see link

For coverage in specific issues of MedMarkets, see link.

For details on the Medtech Startups Database, see link.

Tags: medtech, startup
Click Here to read the entire article...
• Impotence drugs help treat brain tumors: study (Reuters)

A box of Viagra, typically used to treat erectile dysfunction, is seen in a pharmacy in Toronto January 31, 2008. (Mark Blinch/Reuters)Reuters - Impotence drugs may help carry cancer-fighting drugs through the brain to treat malignant tumors, U.S. researchers reported on Monday.
Click Here to read the entire article...
• [Neuroscience] A {gamma}-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains

In prion-infected mice, both the Notch-1 intracellular domain transcription factor (NICD) and the disease-causing prion protein (PrPSc) increase in the...
Click Here to read the entire article...
Cystic Fibrosis News From Medical News Today
By editors@medicalnewstoday.com (MNT Editors) - Copyright 2008 Medical News Today - version: v1.5 build A